Latest Property Portfolio News

Anatara Lifesciences has expanded its intellectual property footprint with a 20-year patent granted in Hong Kong for its GaRP gastrointestinal health product, following similar approvals in Europe and Australia. This milestone strengthens its commercial position in the lucrative global market for digestive health solutions.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Abacus Storage King reports a 5.5% uplift in its property portfolio valuation as of March 2025, driven by improved operations and recent developments. This boost is expected to increase net tangible assets by around $0.13 per security.

Growthpoint Properties Australia has raised its FY25 funds from operations guidance and expanded its logistics portfolio with a $40 million industrial asset acquisition in Queensland, signaling strong operational momentum.

ANZ Group Holdings Limited posted a 7% increase in statutory profit to AUD 3.642 billion for the half year ended 31 March 2025, with stable cash profit and an 83 cent interim dividend. The full integration of Suncorp Bank underpinned lending and deposit growth, while credit impairments eased.

Nanoveu Limited spotlighted its cutting-edge ultra-low-power AI semiconductor technology and strategic collaborations at the Pitt Street Research Semiconductor Conference 2025, signaling a bold push into edge AI markets.

Anagenics Limited has completed a significant restructuring to simplify operations and issued 35 million shares to FOS Capital as part of this process. The company confirms its going concern status and outlines plans for organic and acquisitive growth over the next year.

WOTSO Group reports robust expansion with 31 flexible workspace locations and a $299 million property portfolio, trading at a notable discount to net asset value. The company’s suburban focus and operational discipline underpin sustained revenue and occupancy gains.

ClearVue Technologies has secured its first commercial rooftop contract in Sydney’s CBD, supplying innovative solar glass for the City Tattersalls Club redevelopment to boost sustainability and energy efficiency.

FBR Limited wraps up its US Demonstration Program, secures $6.3 million in capital, and appoints Mark Pivac as CEO amid a 70% cost reduction drive. Strategic collaborations with Samsung Heavy Industries and Liebherr signal broader automation ambitions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

First Graphene Limited reported a successful A$2.4 million capital raise alongside promising progress in its PureGRAPH-CEM product trials in the UK and South Africa, while securing key patents and expanding distribution across Asia and South America.